Synergism of dendritic cell vaccination and anti-PD-L1 immune check-point blockade to sensitize recurrent glioblastoma to anti-tumoral immunity
Sponsor: Heinrich-Heine-Universitaet Duesseldorf
Phase: 1
Disease: Recurrent glioblastoma
EU trial number: 2026-525397-19-00
Population: Adults aged 18–75 years with IDH-wildtype WHO grade 4 glioblastoma at first recurrence, eligible for re-resection after standard chemoradiation and at least three temozolomide cycles, able to produce autologous tumor lysate-based DC vaccine.
Register Investigator Interest
Interested in offering this trial to suitable patients?